Angeles Clinic featured at Society for Melanoma Research
Data presented at International Melanoma Congress
Data from Melanoma specific clinic trials performed at The Angeles Clinic and Research Institute are currently being presented at the 2012 Society of Melanoma Research meeting in Hollywood, CA. Information gathered from trials looking at parp inhibition, braf and mek combinatorial therapy, immunotherapeutics including PD-1 targeted antibody will be presented; these trials were available through the Clinical Research Program at The Angeles Clinic. Additional data on upcoming therapeutics including immunotherapeutics and targetted therapy (nras, PI3K) will be discussed. Dr. Hamid, Director of the Melanoma Program, will be presenting data form the MK-3475 anti-PD-1 antibody on Sunday November 11 as a LATE BREAKING ABSTRACT.
Featured in the American Society of Clinical Oncology (ASCO) Post - Dr. Hamid, Director of the Melanoma Program at The Angeles Clinic, discusses state of the art adjuvant and metastatic therapy for malignant melanoma.
- State of the Art Therapy
- Braf targeted therapy
The Angeles Clinic Breast Cancer Advisor
It is an exciting time full of promise in breast cancer care. Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here
Phase 1 Clincal Program expands at The Angeles Clinic
Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner. Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal. Predictive oncology biomarkers - i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity. Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients. For more information; click here
Angeles Clinic featured at Society for Melanoma Research
Data presented at International Melanoma Congress
Data from Melanoma specific clinic trials performed at The Angeles Clinic and Research Institute are currently being presented at the 2012 Society of Melanoma Research meeting in Hollywood, CA. Information gathered from trials looking at parp inhibition, braf and mek combinatorial therapy, immunotherapeutics including PD-1 targeted antibody will be presented; these trials were available through the Clinical Research Program at The Angeles Clinic. Additional data on upcoming therapeutics including immunotherapeutics and targetted therapy (nras, PI3K) will be discussed. Dr. Hamid, Director of the Melanoma Program, will be presenting data form the MK-3475 anti-PD-1 antibody on Sunday November 11 as a LATE BREAKING ABSTRACT.
Featured in the American Society of Clinical Oncology (ASCO) Post - Dr. Hamid, Director of the Melanoma Program at The Angeles Clinic, discusses state of the art adjuvant and metastatic therapy for malignant melanoma.
- State of the Art Therapy
- Braf targeted therapy
The Angeles Clinic Breast Cancer Advisor
It is an exciting time full of promise in breast cancer care. Researchers and clinicians are continuing to move the field forward at a pace that is difficult to imagine, therefore a well educated public is also critical. It is for this reason that this newsletter has been created; dedicated to all who have experienced breast cancer and those who are simply interested in being informed. Click here
Phase 1 Clincal Program expands at The Angeles Clinic
Success developing targeted therapies in oncology depends on the ability to identify new targets and develop agents that hit those targets in an efficient manner. Major clinical advances in the care of common cancers have been made through participation of patients in Phase I clinical trials of agents that achieve this goal. Predictive oncology biomarkers - i.e., genes and genetic mutations, proteins and signalling pathways implicated in the proliferation and death of cancer cells - and their use to control tumor growth has been a major advancement allowing more efficacious therapy with decreased toxicity. Our collaboration with pharmaceutical partners has been instrumental in bringing this care to our patients. For more information; click here